PL378023A1 - Merkaptoimidazole jako związki antagonistyczne receptora CCR2 - Google Patents
Merkaptoimidazole jako związki antagonistyczne receptora CCR2Info
- Publication number
- PL378023A1 PL378023A1 PL378023A PL37802304A PL378023A1 PL 378023 A1 PL378023 A1 PL 378023A1 PL 378023 A PL378023 A PL 378023A PL 37802304 A PL37802304 A PL 37802304A PL 378023 A1 PL378023 A1 PL 378023A1
- Authority
- PL
- Poland
- Prior art keywords
- mercaptoimidazoles
- receptor antagonists
- ccr2 receptor
- ccr2
- antagonists
- Prior art date
Links
- OXFSTTJBVAAALW-UHFFFAOYSA-N 1,3-dihydroimidazole-2-thione Chemical class SC1=NC=CN1 OXFSTTJBVAAALW-UHFFFAOYSA-N 0.000 title 1
- 102000004497 CCR2 Receptors Human genes 0.000 title 1
- 108010017312 CCR2 Receptors Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2003/001038 WO2004069809A1 (en) | 2003-02-03 | 2003-02-03 | Mercaptoimidazoles as ccr2 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL378023A1 true PL378023A1 (pl) | 2006-02-20 |
Family
ID=32842648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL378023A PL378023A1 (pl) | 2003-02-03 | 2004-01-30 | Merkaptoimidazole jako związki antagonistyczne receptora CCR2 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7511068B2 (pl) |
| EP (1) | EP1592670A1 (pl) |
| JP (1) | JP2006516589A (pl) |
| CN (1) | CN1745069A (pl) |
| AU (2) | AU2003215549A1 (pl) |
| CA (1) | CA2513109A1 (pl) |
| PL (1) | PL378023A1 (pl) |
| WO (2) | WO2004069809A1 (pl) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003215549A1 (en) * | 2003-02-03 | 2004-08-30 | Janssen Pharmaceutica N.V. | Mercaptoimidazoles as ccr2 receptor antagonists |
| AR049386A1 (es) | 2004-05-26 | 2006-07-26 | Janssen Pharmaceutica Nv | Mercaptoimidazoles como antagonistas del receptor ccr2 |
| CN1956976A (zh) * | 2004-05-26 | 2007-05-02 | 詹森药业有限公司 | 作为ccr2受体拮抗剂的巯基咪唑化合物 |
| EP1778646A1 (en) * | 2004-08-11 | 2007-05-02 | Janssen Pharmaceutica N.V. | Mercaptoimidazoles as ccr2 receptor antagonists |
| US20080076120A1 (en) * | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
| JP2010511661A (ja) | 2006-12-07 | 2010-04-15 | エフ．ホフマン−ラ ロシュ アーゲー | Ｖ１ａ受容体アンタゴニストとしてのスピロ−ピペリジン誘導体 |
| MX2009006454A (es) | 2006-12-22 | 2009-06-26 | Hoffmann La Roche | Derivados de espiro-piperidina. |
| ATE536356T1 (de) | 2007-01-12 | 2011-12-15 | Hoffmann La Roche | Spiropiperidin-glycinamid-derivate |
| US9012159B2 (en) | 2009-02-04 | 2015-04-21 | Janssen Research & Development, Llc | Cell based screening assays for the triglyceride synthesis pathway |
| EP2771484A1 (en) | 2011-10-28 | 2014-09-03 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| EP3338776A1 (en) | 2012-05-01 | 2018-06-27 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
| CN112368011A (zh) | 2018-04-11 | 2021-02-12 | 俄亥俄州创新基金会 | 缓释微粒用于眼用药物递送的方法和组合物 |
| US20210317461A1 (en) | 2018-08-09 | 2021-10-14 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| ES2963356T3 (es) * | 2019-06-12 | 2024-03-26 | Nouryon Chemicals Int Bv | Método para aislar ácido carboxílico a partir de una corriente lateral acuosa |
| JP7336541B2 (ja) | 2019-06-12 | 2023-08-31 | ヌーリオン ケミカルズ インターナショナル ベスローテン フェノーツハップ | 過酸化ジアシルを生成するためのプロセス |
| US12215074B2 (en) | 2019-06-12 | 2025-02-04 | Nouryon Chemicals International B.V. | Process for the production of peroxyesters |
| EP3983370B1 (en) | 2019-06-12 | 2023-08-02 | Nouryon Chemicals International B.V. | Process for the production of diacyl peroxides |
| WO2020249690A1 (en) | 2019-06-12 | 2020-12-17 | Nouryon Chemicals International B.V. | Process for the production of diacyl peroxides |
| CN114292236A (zh) * | 2021-12-24 | 2022-04-08 | 江苏慈星药业有限公司 | 一种依托咪酯中间体的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5138069A (en) * | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
| US4835154A (en) * | 1987-06-01 | 1989-05-30 | Smithkline Beckman Corporation | 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors |
| US5354867A (en) * | 1988-12-06 | 1994-10-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
| US5312828A (en) * | 1989-06-14 | 1994-05-17 | Finkelstein Joseph A | Substituted imidazoles having angiotensin II receptor blocking activity |
| US6028091A (en) * | 1990-12-14 | 2000-02-22 | Smithkline Beecham Plc | Medicament |
| US6034114A (en) * | 1990-12-14 | 2000-03-07 | Smithkline Beecham Plc | Medicament |
| GB9803226D0 (en) * | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| SE9802937D0 (sv) * | 1998-09-01 | 1998-09-01 | Astra Pharma Prod | Novel compounds |
| EP1202747A1 (en) * | 1999-07-20 | 2002-05-08 | Merck & Co., Inc. | Sustained release drug dispersion delivery device |
| GB0000626D0 (en) * | 2000-01-13 | 2000-03-01 | Zeneca Ltd | Chemical compounds |
| AU2003215549A1 (en) * | 2003-02-03 | 2004-08-30 | Janssen Pharmaceutica N.V. | Mercaptoimidazoles as ccr2 receptor antagonists |
-
2003
- 2003-02-03 AU AU2003215549A patent/AU2003215549A1/en not_active Withdrawn
- 2003-02-03 WO PCT/EP2003/001038 patent/WO2004069809A1/en not_active Ceased
-
2004
- 2004-01-30 AU AU2004210071A patent/AU2004210071A1/en not_active Abandoned
- 2004-01-30 CN CNA200480003283XA patent/CN1745069A/zh active Pending
- 2004-01-30 PL PL378023A patent/PL378023A1/pl not_active Application Discontinuation
- 2004-01-30 EP EP04706674A patent/EP1592670A1/en not_active Withdrawn
- 2004-01-30 WO PCT/EP2004/000957 patent/WO2004069810A1/en not_active Ceased
- 2004-01-30 CA CA002513109A patent/CA2513109A1/en not_active Abandoned
- 2004-01-30 US US10/544,569 patent/US7511068B2/en not_active Expired - Fee Related
- 2004-01-30 JP JP2006501712A patent/JP2006516589A/ja active Pending
-
2008
- 2008-12-16 US US12/335,957 patent/US20090192206A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004210071A1 (en) | 2004-08-19 |
| WO2004069809A1 (en) | 2004-08-19 |
| CA2513109A1 (en) | 2004-08-19 |
| US20060058289A1 (en) | 2006-03-16 |
| EP1592670A1 (en) | 2005-11-09 |
| US20090192206A1 (en) | 2009-07-30 |
| CN1745069A (zh) | 2006-03-08 |
| JP2006516589A (ja) | 2006-07-06 |
| WO2004069810A1 (en) | 2004-08-19 |
| AU2003215549A1 (en) | 2004-08-30 |
| US7511068B2 (en) | 2009-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI346553B (en) | Chemokine receptor antagonists | |
| PT1638969E (pt) | Antagonistas do receptor de cgrp | |
| IL182254A0 (en) | Substituted dipiperidine ccr2 antagonists | |
| AU2003261392A8 (en) | M3muscarinic acetylcholine receptor antagonists | |
| IL174538A0 (en) | Thrombin receptor antagonists | |
| IL237513A0 (en) | Piperazindiones as oxytocin receptor antagonists | |
| AU2003215549A1 (en) | Mercaptoimidazoles as ccr2 receptor antagonists | |
| IL173512A0 (en) | Cyclopropyl derivatives as nk3 receptor antagonists | |
| GB0417601D0 (en) | Assay device & method | |
| IL172822A0 (en) | Muscarnic acetylcholine receptor antagonists | |
| PL1636206T3 (pl) | Pochodne imidazolu jako antagoniści receptorów glutaminianu | |
| PL378753A1 (pl) | Antagoniści receptora CCR-3 | |
| EP1631559A4 (en) | IL-8 SB / SB RECEPTOR ANTAGONISTS | |
| EP1812008A4 (en) | ANTAGONISTS OF THE IL-8 RECEPTOR | |
| IL178622A0 (en) | Piperazinylpiperidine derivatives as chemokine receptor antagonists | |
| SG131946A1 (en) | Ccr3 receptor antagonists | |
| AU2003287219A8 (en) | Il-8 receptor antagonists | |
| ZA200609846B (en) | Mercaptoimidazoles as CCR2 receptor antagonists | |
| EP1636230A4 (en) | ADENOSINE A1 RECEPTOR ANTAGONISTS | |
| IL173337A0 (en) | Receptor | |
| GB0302094D0 (en) | EP4 receptor antagonists | |
| ATE411989T1 (de) | Mercaptoimidazole als ccr2-rezeptorantagonisten | |
| GB0414798D0 (en) | Receptor | |
| ZA200608369B (en) | Piperazinylpiperidine derivatives as chemokine receptor antagonists | |
| GB0321998D0 (en) | Receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |